Bohica have a few questions, tried to find: out how much cash they have (got a few different answers)?
Also how long will the cash last?
the Generic deals look good but was not sure how much it would add to the bottom line, in terms of cash flow for next year.
there drug Satraplatin (phase 3) cancer drug (oral) has been fast tracked and a good partner, looks good do not know the terms of the partnership and how much revenue they are expecting from the drug.
Elcamitrucin (spelling names are very longLOL) phase 2 seems good.
the main concern for me would be the same as yours Bohica. The stock seemed to jump on news that they were not going to be delisted from Nasdaq. It looks like managment is trying to turn this around, (seems to have gotten carried away with spending in 2002).
When it comes to Junior drug companies other people on this board have more knowledge than me, ussually play junior oil/gas and gold/mining plays (should have played more golds, moose pasture has gone up across the world, and some tech.
the stock hit a low of $1.66 high $10.37 recently $6.61 up .64 on the news. and have 4.66 million shares outstanding.
the most important aspect of most junior drug stocks is cash on hand, and how long it will last. This is important because when capital markets dry up and you canot get more financing you can have the greatest drug pipeline in the world; and you are still in trouble.
can list you dozens of junior drug stocks that have good pipelines and not enough cash.
will watch the stock as it is having a good run.
good luck with the stock.
thanks
selkirk
